Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Barr Claravis 30 Mg Dose Will Compete With Ranbaxy’s Isotretinoin Generic

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Roche markets Accutane in 10 mg, 20 mg and 40 mg doses only.

You may also be interested in...



Cipher Receives “Approvable” Letter For CIP-Isotretinoin

FDA letter appears to resolve questions about the appropriate pathway for the acne medication.

Accutane iPLEDGE Debut On Track Despite Calls For Delay

FDA confirmed that it would not delay the March 1 implementation of the isotretinoin risk management program.

Pfizer and BioNTech To Initiate COVID-19 Vaccine Clinical Trials In April

The two companies announced more details about their COVID-19 vaccine development plan, including a $185m upfront payment and $113m equity investment from Pfizer.

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

PS064138

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By